Abstract
Cognitive decline is a common symptom in multiple sclerosis patients, with profound effects on the quality of life. A nonhuman primate model of multiple sclerosis would be best suited to test the effects of demyelination on complex cognitive functions such as learning and reasoning. Cuprizone has been shown to reliably induce brain demyelination in mice. To establish a nonhuman primate model of multiple sclerosis, young adult cynomolgus monkeys were administered cuprizone per os as a dietary supplement. The subjects received increasing cuprizone doses (0.3–3% of diet) for up to 18 weeks. Magnetic resonance imaging and immunohistological analyses did not reveal demyelination in these monkeys.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 208-213 |
| Number of pages | 6 |
| Journal | Annals of Clinical and Translational Neurology |
| Volume | 2 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2015 |
Bibliographical note
Funding Information:We thank Christopher L. Nelson for scientific discussion and editorial support, Timothy Myshrall for advice, and Derrek Tew for technical support. This investigation was supported by an imaging pilot fund from the Department of Radiology at the Cleveland Clinic (to J. T. C.) and by a pilot grant from the National Multiple Sclerosis Society (PP1866 to B. D. T.).
Funding Information:
This investigation was supported by an imaging pilot fund from the Department of Radiology at the Cleveland Clinic (to J. T. C.) and by a pilot grant from the National Multiple Sclerosis Society (PP1866 to B. D. T.).
Publisher Copyright:
© 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.